Leukotriene pathway in sickle cell disease: a potential target for directed therapy.
Expert Rev Hematol
; 2(1): 57-68, 2009 Feb.
Article
em En
| MEDLINE
| ID: mdl-21082995
ABSTRACT
Sickle cell disease (SCD) is characterized by recurrent episodes of vaso-occlusion, resulting in tissue ischemia and end-organ damage. Inflammation is critical to the pathogenesis of vaso-occlusion and has been associated with SCD-related morbidity and mortality. Despite the impact of inflammation, no directed anti-inflammatory therapies for the treatment or prevention of vaso-occlusive events currently exist. Among individuals with SCD, asthma is a comorbid inflammatory condition that increases the risk of pain episodes, acute chest syndrome and death. Inflammation associated with asthma could augment the proinflammatory state of SCD, increasing episodes of vaso-occlusion. Leukotrienes are inflammatory mediators that play a prominent role in the pathogenesis of asthma and have been associated with SCD-related morbidity. Targeting inflammatory mediators, such as leukotrienes, is a promising approach for the development of novel therapies for the treatment of SCD. This review will examine the relationship between inflammation and vaso-occlusion, with particular focus on the leukotriene pathway.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucotrienos
/
Anemia Falciforme
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article